Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Hayton (Manchester, United Kingdom), D. Terrington (Norwich, United Kingdom), W. Ahmed (Manchester, United Kingdom), I. White (Manchester, United Kingdom), M. Wilkinson (Manchester, United Kingdom), K. Vekaria (Manchester, United Kingdom), N. Chaudhuri (Manchester, United Kingdom), A. Wilson (Norwich, United Kingdom), C. Leonard (Manchester, United Kingdom), S. Fowler (Manchester, United Kingdom). Exhaled volatile organic compounds in idiopathic pulmonary fibrosis and disease progression. 727

Member's Comments

No comment yet.

Related content which might interest you: Analysis of semi-volatile organic compounds in exhaled breath condensate of patients with obstructive lung diseases Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Exhaled breath condensate markers in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 334s Year: 2005 Value of exhaled volatile organic compounds in monitoring airway disease Source: School Course 2013 - Monitoring of asthma, COPD and other airway diseases Year: 2013 Exhaled air volatile organic compounds and eosinophilic airway inflammation in asthma Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Exhaled breath condensate - a new tool for assessment of idiopathic pulmonary fibrosis? Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Exhaled nitric oxide in patients with idiopathic pulmonary fibrosis and pulmonary hypertension Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Epithelial alarmin levels in exhaled breath condensate in patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Exhaled carbon monoxide measurement in patients with interstitial lung diseases (ILD) Source: Annual Congress 2008 - Clinical aspects of interstitial lung disease Year: 2008 Exhaled hydrogen sulfide in patients with chronic airway inflammatory disease Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers Year: 2011 Exhaled volatile organic compounds as biomarkers for respiratory diseases Source: Eur Respir Monogr 2010; 49: 130-139 Year: 2010 Fractional exhaled nitric oxide in patients with chronic obstructive pulmonary disease Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification Year: 2019 Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis Source: Eur Respir J 2006; 27: 929-936 Year: 2006 Multiple detectable exhaled volatile organic compounds (vocs) may serve as potential inflammatory biomarkers in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009 NO metabolites in exhaled breath condensate in cystic fibrosis patients: correlation with pulmonary function, nutritional status and systemic inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 715s Year: 2006 Reproducibility of exhaled breath condensate pH in chronic obstructive pulmonary disease Source: Eur Respir J 2005; 25: 269-274 Year: 2005 Volatile organic compounds (VOC) in exhaled breath of patients with COPD Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in chronic and acute airway diseases Year: 2010 Exhaled volatile organic compounds in nonrespiratory diseases Source: Eur Respir Monogr 2010; 49: 140-151 Year: 2010